DD. This drug was approved 9 months ago. It is not an end all cancer drug It is a last chance treatment after competitor's first and second line therapies don't work, hence it is labeled a third-line chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) treatment. The most recent PR stating that it for all oncology indications is a downright falsehood and deceptive to potential investors. Also the drug has serious adverse side effects. Copiktra was originally being developed by Infinity Pharmaceuticals and AbbVie. AbbVie walked away from the partnership in 2016 upon seeing the weak Phase II results.
This article says it all. Investors don't be deceived!
Market Data 
Markets 
